Skip to main content

COVID-19

ORD is available to assist faculty members in procuring federal funding for COVID-19-related research projects. Our staff can provide personalized guidance to faculty, including identifying funding opportunities, finding collaborators, facilitating connections with program officers, and advising on strategic approaches to developing a proposal.

COVID-19-related funding opportunities are disseminated weekly via ORD Insight (ORD’s funding opportunity newsletter; subscribe here). Please see the cumulative list of more than 50 federal, foundation, and corporate funding opportunities as well as grant-related resources below.

Featured Funding Opportunities

NEW! Radx-rad Initiatives

RADx-rad will support new, non-traditional approaches, including rapid detection devices and home-based testing technologies, that address current gaps in COVID-19 testing. The program will also support new or non-traditional applications of existing approaches to make them more usable, accessible, or accurate. These may lead to new ways to identify the current SARS-CoV-2 virus as well as potential future viruses.

NEW! XPRIZE Rapid COVID Testing
Registration deadline is 8/31/20

XPRIZE Rapid Covid Testing is a $5 million dollar, 6-month competition to develop faster, cheaper, and easier to use COVID-19 testing methods at scale. No more guessing. No more lack of tests. Five team will be funded at $1 million per team.

The world needs more high-quality, affordable testing to safely re-open. The winning teams will develop COVID-19 tests that are radically affordable compared to what’s currently available on the market. For about the price of a latte, the tests will be equal to (or better than) commercial offerings at measuring sensitivity, specificity, and limit of detection, with a maximum turnaround time of 12-hours from sample to result. The winning teams will also be able to successfully deploy and conduct a minimum of 500 tests per week at a live testing site within 60 days, and have the potential to scale their solutions to thousands of tests per week.

NEW! $50k Seed Funding & Workshop COVID-19 and Beyond: Northwestern / Tel Aviv University Joint Research Projects
Submission deadline is 8/16

The Northwestern University (NU) – Tel Aviv University (TAU) Joint Research Program on COVID-19 will offer two $50K seed funding awards on interdisciplinary collaborative COVID-19 research between the two institutions.  To get help finding a partner researcher at Tel Aviv University, send a short 1 sentence description of your research interests to Prof. Itai Benhar at Tel Aviv University Benhar@tauex.tau.ac.il:  The proposal deadline is  Aug 15.  For additional information please email:  global.initiatives@northwestern.edu

Funding Opportunities

Internal Funding

NEW! $50k Seed Funding & Workshop COVID-19 and Beyond: Northwestern / Tel Aviv University Joint Research Projects
Submission deadline is 8/16

The Northwestern University (NU) – Tel Aviv University (TAU) Joint Research Program on COVID-19 will offer two $50K seed funding awards on interdisciplinary collaborative COVID-19 research between the two institutions.  To get help finding a partner researcher at Tel Aviv University, send a short 1 sentence description of your research interests to Prof. Itai Benhar at Tel Aviv University Benhar@tauex.tau.ac.il:  The proposal deadline is  Aug 15.  For additional information please email:  global.initiatives@northwestern.edu

 

Department of Defense

Health and Human Services

Notices of Intent

NEW! CDC Emerging Infections Network – Research for Preventing, Detecting, and Managing Travelers who Acquire Infectious Diseases Abroad (RFA-CK-21-002)
Applications are due 2/9/21

The purpose of this notice of funding opportunity is to support research activities that will assist with the prevention, detection, and management of international travelers who become ill during or after travel. The project must have a focus on travel and tropical medicine providers with the capability to participate in research to determine the disease prevention strategies, burden, severity, optimal diagnostics, treatment interventions, and outcomes of infectious diseases acquired while travelling abroad. This research will bridge the gap between clinical medicine and public health by assisting with improving patient care, better understanding the natural history of disease, and implementing optimal diagnostic and treatment strategies, with the ultimate outcome being an advancement in the global health security of the United States.

NEW! NIMH Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 – Clinical Trial Optional) (NOT-MH-20-058)

The National Institute of Mental Health (NIMH) with other ICs is solicit applications to support research to determine the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices] to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and vulnerable populations.

Opportunities for New Awards
NEW! Radx-rad Initiatives

RADx-rad will support new, non-traditional approaches, including rapid detection devices and home-based testing technologies, that address current gaps in COVID-19 testing. The program will also support new or non-traditional applications of existing approaches to make them more usable, accessible, or accurate. These may lead to new ways to identify the current SARS-CoV-2 virus as well as potential future viruses.

LIMITED SUBMISSION: Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)

The RADx-rad Data Coordination Center (DCC) will provide overarching support and guidance to RADx-rad awardees in the following three areas: (1) Administrative Operations and Logistics, (2) Data Collection, Integration and Sharing, and (3) Data Management and Use.

LIMITED SUBMISSION: Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)

This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings.

LIMITED SUBMISSION: Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)

This FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2.

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)

This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes.

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)

The goal of this FOA is to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests.

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 – Clinical Trials Not Allowed)

This FOA will support wastewater-based testing surveillance which can provide detailed mapping of the extent and spread of COVID-19.

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)

This FOA will focus on developing and validation of approaches that bring together inputs from multiple surveillance technologies, not based or focused on direct viral testing of individuals, to facilitate early detection of COVID-19 in facilities at high risk for infections due to the high density of individuals who stay together for prolonged periods of time.

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)

This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time.

HHS SARS-CoV-2 (COVID-19) Program Activities (OS-PAW-20-001)

The Office of the Assistant Secretary for Health (OASH) expects to issue a Broad Agency Announcement to solicit projects that will further enable the coordination and development of COVID-19 testing and associated products that meet the current and future needs, and the effective transition of technology into broad use without impediments. The primary areas of focus should specifically include (1) Scaling and Networking of Technologies, and (2) Testing Demonstrations & Technical Assistance.Specifically, OASH is interested in submissions that will substantially increase our testing capacity and quality in the near term, and do not fall within the scope of other HHS programs.

Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (RFA-DK-20-021)
Applications are due by 12/16/20

NIDDK is soliciting new research in human subjects or model organisms, using isolated tissues, cells, or in vivo approaches to delineate and address mechanisms by which people with diseases in the mission of NIDDK have poor outcomes from SARS-CoV-2 infection, including variable susceptibility, altered course of disease, morbidity and mortality. Research focused on how SARS-CoV-2 and COVID-19 lead to acute or chronic damage to organs, contributing to development of the diseases of interest to NIDDK, is also responsive. The knowledge gained will contribute a new evidence base to accelerate advances in diagnostics, therapeutics, clinical management, and public health innovation, as related to diseases and outcomes of interest to NIDDK.

NEW! COVID-19 Private Sector Engagement & Partnership Fund (SFOP0007088)

The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards.

Through this APS, the Department of State (DOS) announces its desire to engage private sector partners to expand and amplify the Department’s COVID-19 response. The Fund seeks to support private sector interventions and build upon private sector investments in response to the
virus.

NEW! NIH Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required) (RFA-TR-20-003)

The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

NIH Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional) (PAR-20-243)
Applications are due by 8/20/20, 12/2/20, 3/2/21

The purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional) (RFA-RM-20-020)
Applications due by 9/30/20

The NIH Director’s Transformative Research Award Program supports collaborative investigative teams or individual scientists who propose unusually innovative research projects. For this FOA, the project should have the potential to have a broad impact on SARS-Cov-2 prevention, preparation, or response. To be considered transformative, projects must have the potential to create or overturn fundamental scientific paradigms through novel concepts or perspectives, transform the way research is conducted through the development of novel tools or technologies, or lead to major improvements through the development of highly innovative diagnostic, therapeutic, or preventive strategies. Consistent with this focus, Transformative Research Award applications should propose research substantially different from current mainstream research.

NIDCD Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders (NOT-DC-20-008)
Due dates vary by mechanism; Notice expires on 9/8/22

NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

NIH Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) (PAR-20-237)
Applications due 8/28/20; 12/1/20

This FOA encourages research with NIH-designated health disparity populations and other vulnerable groups on community interventions to address the adverse psychosocial, behavioral, and socioeconomic effects of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Applications are sought to test: 1) the impacts of mitigation strategies to prevent COVID-19 transmission and acquisition; and 2) already implemented, new, or adapted interventions to address the adverse consequences of the pandemic on the health of these groups. Projects may evaluate existing or ongoing community-based programs or policies (referred to hereafter as natural experiments) or prospectively test new or adapted interventions (referred to as prospective interventions). Projects should be designed to test hypotheses about mechanisms of action that account for an intervention’s effects; mechanisms may operate at any level of analysis.

Biomedical Advanced Research and Development Authority (BARDA) BAA Amendment (BAA-18-100-SOL-00003)
White papers are due on 7/30/20 and 10/31/20

BARDA is soliciting applications for topics specifically relating to COVID-19, including diagnostic assays, point-of care-diagnostic assays, vaccines, therapeutics, prophylaxis, respiratory protective devises, and ventilators.

NIAID Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-051)
Standard R03 application due dates (Notice expires on 09/08/21)

National Institute of Allergy and Infectious Diseases (NIAID) is encouraging the submission of R03 applications on: critical aspects of viral infection, replication, pathogenesis, and transmission; evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence; clinical diagnostic tests; therapeutics against multiple coronavirus strains; cellular and humoral immune responses to infection; and vaccine candidates including approaches for pan-coronavirus protection, that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.

NIAID Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) (PAR-20-177)
Application accepted on a rolling basis until 4/30/21

National Institute of Allergy and Infectious Diseases (NIAID) is providing an expedited funding mechanism for research on SARS-CoV-2 and COVID-19 to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures and to share findings quickly and broadly. Applications submitted should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.

NIAID Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) (PAR-20-178)
Application accepted on a rolling basis until 4/30/21

National Institute of Allergy and Infectious Diseases (NIAID) is providing an expedited funding mechanism for research on SARS-CoV-2 and COVID-19 to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures and to share findings quickly and broadly. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using this R01 mechanism.

NIEHS Notice of Special Interest (NOSI): Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (NOT-ES-20-020)
Applications will be accepted on a rolling basis until 5/4/21

NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. Research interests include but are not limited to examining the role of environmental exposures in impacting individual susceptibility to SARS-Cov-2 infection, or the development and severity of COVID-19 disease, determining the potential health effects of increased personal/community use of disinfection products for COVID-19 control, and investigating the role of lifestyle factors (e.g. diet, physical activity) as modifiers of the effects of environmental exposures on the development or severity of COVID-19 disease.

NCATS Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)
Application due dates vary by mechanism (Notice expires on 10/17/20)

National Center for Advancing Translational Sciences (NCATS) is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.  Grant mechanisms include Bench Testing (UG3/UH3), Clinical Trial Planning (U34), or Clinic Testing (U01).

Notice of Additional Due Date and Additional Areas of Focus Especially of Interest of PAR-19-373 and PAR-19-384, “Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)” (NOT-OD-20-103)
Applications are due on June 8, 2020; March 17, 2021

The Purpose of this Notice is to add a new due date (6/8/20) and additional areas of focus related to COVID-19 for PAR-19-373 and PAR-19-384. These funding opportunities solicit research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing.

Supplements/Revisions to Existing Awards

NEW! NIMHD Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations (NOT-MD-20-022)
Applications will be accepted on a rolling basis until 12/15/20

Research is needed to test community interventions focused on the prevention (or slowing) of COVID-19 transmission, evaluate local and state policies and programs intended to mitigate COVID-19 exposure and improve adherence, and reduce the negative impact of the multifaceted consequences on the health of populations who experience health disparities and other vulnerable groups. This work may include leveraging and scaling existing resources (e.g., health education materials, technology, social media, mass media, social support networks, social services). In domains and populations in which the evidence base is limited, the development, testing, and implementation of novel or adapted interventions to address the negative health consequences of the COVID-19 pandemic (including the unintended health consequences of population-level interventions) may also be needed to address the unique needs of populations.

NCI Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis (NOT-CA-20-054)

The National Cancer Institute (NCI) will consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources under the following conditions: Any proposed COVID-19 projects would have to be novel, innovative, compelling, and scientifically meritorious. Projects should have cancer relevance and the potential for high impact. Proposed projects should not duplicate other efforts or be simple extensions or modifications of ongoing research. Proposed projects must be able to start immediately and be time limited, not to exceed 1 year.

NEW! NCCIH Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19) (NOT-AT-20-012)
Applications will be accepted until 8/18/20

The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NCCIH is particularly interested in projects focusing on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product–based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations.

NIAAA Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA (NOT-AA-20-011)
Applications will be accepted until 4/16/21

The National Center for Complementary and Integrative Health (NCCIH) announces the availability of funds for Administrative Supplements or Urgent Competitive Revisions to promote research on the effects of natural products alone or in combination with other complementary and integrative health approaches on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NCCIH is particularly interested in projects focusing on the therapeutic and/or mechanistic effects on SARS-CoV-2/COVID-19 of natural product–based complementary remedies including, but not limited to: herbal therapies, vitamins, supplements, probiotics, microbial therapies, and Chinese medicine herbal preparations.

This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

NIBIB Rapid Acceleration of Diagnostics (RADx)
Proposals are being accepted on a rolling basis until further notice

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution.

NIBIB Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-007)
Applications will be accepted until 3/31/21

The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Example technologies include, but are not limited to rapid point-of-care and home-based testing/diagnostics; wearable, implantable, and remote sensors/imagers for physiological monitoring and medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection.

NIBIB Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-008)
Applications will be accepted on a rolling basis until 11/10/20

The NIBIB is seeking applications from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years. Technologies include, but are not limited to rapid point-of-care and home-based testing/diagnostics; medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection Non-contact sensing and imaging for rapid mass screening and vital sign assessment.

NIEHS Notice of Special Interest (NOSI): Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (NOT-ES-20-020)
Applications will be accepted on a rolling basis until 5/4/21

NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. Research interests include but are not limited to examining the role of environmental exposures in impacting individual susceptibility to SARS-Cov-2 infection, or the development and severity of COVID-19 disease, determining the potential health effects of increased personal/community use of disinfection products for COVID-19 control, and investigating the role of lifestyle factors (e.g. diet, physical activity) as modifiers of the effects of environmental exposures on the development or severity of COVID-19 disease.

NIGMS Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Applications will be accepted on a rolling basis until 2/5/21

National Institute of General Medical Sciences (NIGMS) will accept the submission of applications to address incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants), repurpose/modify diagnostics tools for rapid detection (SBIR/STTR only) and development of therapeutics (SBIR/STTR only).  Applications must be submitted to PA-18-935 which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

NIAID Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-034)
Applications will be accepted on a rolling basis until 3/25/21

National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.  Applications must be submitted to PA-20-135 which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

NIA Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-20-022)
Applications will be accepted on a rolling basis until 5/1/21

In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address multiple areas of interest within the mission of NIA.

NHLBI Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-HL-20-757)
Applications accepted on rolling basis until 10/5/20

The National Heart, Lung, and Blood Institute (NHLBI) encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and heart, lung, and blood COVID-19 disease. Or particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection.

NHLBI Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials
Applications accepted on a rolling basis from 5/1/20 through 10/5/20

NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19. It is strongly recommended that the parent activity code be one of the following: P01R01R33R41R42R43R44U01U24U54UH3, or UM1.

Topics of specific interest to the NHLBI include the safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases.

NIDA Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)
Applications will be accepted on a rolling basis through 3/31/21

National Institute on Drug Abuse (NIDA) is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications must be submitted using the following funding opportunities: PA-18-935, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant, or PA-18-591, which is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

NEW! NIH Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-121)
Notice expires on 8/8/20

This Notice highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. This Testing Research Projects NOSI will support supplements to NIH grantees that are part of large-scale networks, consortia, centers and other current programs that have adequate capacity, infrastructure, and established community-engaged relationships to support large-scale testing.

NEW! NIH Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-120)

This Notice highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. This Testing Research Projects NOSI will support supplements to individual NIH research awards that include community collaborations or partnerships to support COVID-19 testing (or have the capacity to ramp up quickly) to reach underserved and/or COVID-19 vulnerable populations.

NEW! NIH Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-119)
Notice expires on 9/9/20

This Notice highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The purpose of this SEBI Notice is to identify, analyze, and address the social, ethical, and behavioral factors likely to influence access and uptake of COVID-19 testing in underserved and/or vulnerable populations. Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards.

NIH Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (NOT-MH-20-053)
Applications will be accepted on a rolling basis until December 15, 2020

The purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact. Existing digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices, and personalized medicine] provide opportunities to help consumers and clinicians manage and improve health during and following population level healthcare and other critical disruptions.

NIH Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Applications accepted on a rolling basis until 4/15/21

NIMH is interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health.

NIH Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Applications accepted on a rolling basis until 5/1/21

This notice is soliciting research in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.

NIH Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NOT-OD-20-097)
Applications accepted until 4/1/21

This special notice encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

NCATS Notice of Special Interest (NOSI): Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-016)
Applications accepted on a rolling basis from 5/15/20 through 1/25/22

NCATS is interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

NCATS Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs (NOT-TR-20-028)
Applications accepted on a rolling basis until 11/10/20

NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients for activities including but not limited to: digital health platforms and models that inform clinical practice, planning of COVID-19 trials, provision of clinical data in specified formats for surveillance or clinical study, and sample provision and assessing infectious or convalescent status.

NCATS Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need (NOT-TR-20-011)
Application due dates vary by mechanism (Notice expires on 7/10/21)

National Center for Advancing Translational Sciences (NCATS) is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).

NCATS Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-017)
Application will be accepted until 1/26/22

NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

AHRQ Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (NOT-HS-20-008)

Agency for Healthcare Research and Quality (AHRQ) intends to publish a new funding opportunity announcement using the R01 mechanism to perform critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic.

NINDS Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System (NOT-NS-20-051)
Applications will be accepted on a rolling basis from 4/15/20 to 4/14/21

National Institute of Neurological Disorders and Stroke (NINDS) is encouraging the submission of applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the Coronovirus that are directly related to the NINDS mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Intelligence Advanced Research Projects Activity (IARPA)

Medical Technology Enterprise Consortium

All MTEC Pre-announcements are posted here: https://www.mtec-sc.org/upcoming-solicitations/

All MTEC active solicitations are posted here: https://www.mtec-sc.org/solicitations/ 

Department of Commerce

NEW! NOAA Climate Program Office FY2021 (NOAA-OAR-CPO-2021-2006389)
Applications are due Nov 30, 2020

Climate Program Office of the National Oceanic and Atmospheric Administration (NOAA) is seeking applications for 6 individual competitions in FY21: 1) Emissions, Air Quality, and Heat in Urban Areas; 2) Atmospheric impacts due to changes in anthropogenic activity during the COVID-19 pandemic; 3) New Climate Monitoring Approaches and Products for Areas of Climate Risk; 4) Process-Oriented Diagnostics for NOAA Climate Model Improvement and Applications; 5) Innovative Ocean Dataset/Product Analysis and Development for support of the NOAA Observing and Climate Modeling Communities; and 6) Advancing Climate Adaptation and Coastal Community Resilience.

NIST Manufacturing USA National Emergency Assistance Program (2020-NIST-MFGUSA-NEAP-01)
Applications will be accepted on rolling basis
(Northwestern is not eligible as the lead institution but may participate on an application.)

National Institute of Standards and Technology (NIST) invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic.  Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

National Science Foundation

NEW! NSF Dear Colleague Letter: Supporting Research on Pandemics within the Civic Innovation Challenge and Broadened NSF Support for the Challenge (NSF 20-100)

This Dear Colleague Letter is to notify the community that research projects focused on pandemics are considered appropriate for the Civic Innovation Challenge (CIVIC; NSF 20-562), a research and action competition in the smart and connected communities (S&CC) domain. Proposing teams may choose to focus on resilience planning related to the continuing COVID-19 crisis, resilience planning for future pandemics, the compound problem of other disasters occurring in the context of pandemic – or they may focus on resilience planning for other forms of natural disasters. Similarly, projects focused on mobility may choose to consider how pandemics shape possible solutions responsive to this track.

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)

This program has been archived. Please see the FAQs which provides guidance for prospective Principal Investigators interested in performing COVID-19-related research.

Patient-Centered Outcomes Research Institute (PCORI)

Foundation Funding

For inquiries and additional foundation funding opportunities, please contact foundationrelations@northwestern.edu

NEW! XPRIZE Rapid COVID Testing
Registration deadline is 8/31/20

XPRIZE Rapid Covid Testing is a $5 million dollar, 6-month competition to develop faster, cheaper, and easier to use COVID-19 testing methods at scale. No more guessing. No more lack of tests. Five team will be funded at $1 million per team.

The world needs more high-quality, affordable testing to safely re-open. The winning teams will develop COVID-19 tests that are radically affordable compared to what’s currently available on the market. For about the price of a latte, the tests will be equal to (or better than) commercial offerings at measuring sensitivity, specificity, and limit of detection, with a maximum turnaround time of 12-hours from sample to result. The winning teams will also be able to successfully deploy and conduct a minimum of 500 tests per week at a live testing site within 60 days, and have the potential to scale their solutions to thousands of tests per week.

Fast Grants

Fast Grants are for PIs already working on projects that could help with the COVID-19 pandemic within the next six months and are in need of additional funding to complete them. Grants are $10k to $500k. This program is currently paused. Please check back for any additional details.

COVID-19 Therapeutics Accelerator

Gates, MasterCard, and the Wellcome Trust are joining forces with an investment of $125M to speed the development and access to treatment of COVID-19. This press release has an email contact for an inquiry if your work is within that area.

Robert Wood Johnson Foundation (RWJF): Pioneering Ideas Exploring the Future to Build a Culture of Health

Proposals will be accepted on a rolling basis throughout the year

Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. The Foundation is interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. RWJF welcomes proposals from scientists, anthropologists, artists, urban planners, and community leaders – anyone, anywhere who has a cutting edge idea that could alter the trajectory of health and increase opportunities for everyone in the United States to live their healthiest life possible.

While this RFP is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, the Foundation recognizes the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

Corporate Funding

For inquiries and additional corporate funding opportunities please add Jim Bray, Director of Corporate Engagement (j-bray@northwestern.edu).

NEW! TD Bank: 2020 TD Ready Challenge
Applications accepted until 8/13/20

The 2020 TD Ready Challenge seeks to provide financial support to organizations that have designed innovative, scalable and/or replicable solutions to help address the pandemic-caused issues faced by communities that are experiencing disproportionate impacts of COVID-19 across North America. Solutions must address at least one (but can address more) of the four interconnected drivers of change of the TD Ready Commitment (Financial Security, Vibrant Planet, Connected Communities and Better Health). We are seeking applications that will help drive accelerated, sustained and equitable recovery.  

Merck KGaA: Stimulating Innovative Research
Applications accepted on a rolling basis until 8/30/20

The threat from newly emerging viral infections is one of the top global challenges for humanity. The recent COVID-19 pandemic shows that pandemic preparedness and having the right products and technology to fight infectious diseases with epidemic and pandemic potential is of utmost importance. It is required to act quickly to limit further substantial damages to society, economy and ecology. Merck will consider project proposals that leverage modern technologies to create new breakthrough solutions to be more prepared for pandemic outbreaks or work towards existing solutions that could help to fight emerging viral infections.

Mozilla Open Source Support Program (MOSS): COVID-19 Solutions Fund
Applications will be accepted on a rolling basis

MOSS will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).

  • MOSS prefers reasonably mature projects that can immediately deploy funding; early stage ideas are unlikely to receive funding.
  • Awardees are expected to use all funds within three months of receiving the award.
  • The MOSS committee will only consider projects which are released publicly under a license that is either a free software license according to the FSF or an open source license according to the OSI. Projects which are not licensed for use under an open source license are not eligible for MOSS funding.

 

Other External Funding

NEW! National Council on Disability (NCD) COVID-19’s Broadscale Impact on the Lives of People with Disabilities (NCD-20-04)
Submissions are due Aug 21, 2020

The National Council on Disability (NCD) seeks proposals for a cooperative agreement to develop NCD’s annual progress report which will examine COVID-19’s broadscale impacts on people with disabilities in seven major areas: nondiscriminatory access to healthcare; the direct care workforce; group housing; education; employment; mental health; and communications. The report will also include a discussion of the intersection of disability and race, and of transportation impacts. The research and findings in this report will provide policymakers, including the White House and Congress, and federal agencies, with insight needed to make policy decisions to improve the current and future welfare of people with disabilities in a national emergency like the COVID-19 pandemic. The report will also provide people with disabilities information on federal policy, legislation, and initiatives related to emergency preparedness and response.

COVID-19 High Performance Computing (HPC) Consortium Request for Proposals
Applications may be submitted anytime

The COVID-19 High Performance Computing Consortium is a unique private-public effort to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium, which will then be reviewed for matching with computing resources from one of the partner institutions.

Archived

Chicago Coronavirus Assessment Network (Chicago CAN)

Robert Wood Johnson Foundation (RWJF) – Systems for Action: Supplemental Research on COVID-19 Response and Recovery

NIH Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional) (RFA-CA-20-039)

NIH Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional) (RFA-CA-20-038)

data.org Inclusive Growth and Recovery Challenge

Chicago Biomedical Consortium (CBC) COVID-19 Response

COVID-19 Detect & Protect Challenge

AWS Diagnostic Development Initiative

Equitable Recovery: Research to Boost Workers’ Economic Security and Mobility

IARPA COVID-19 Seedling Research Topics (IARPA-BAA-20-01)

Society for Medical Decision Making (SMDM) COVID-19 Decision Modeling Grant

AHRQ Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (NOT-HS-20-008)

NCI Notice of Intent to Publish a Funding Opportunity Announcement for Serological Sciences Centers of Excellence (NOT-CA-20-066)

NIMHD Notice of Intent to Publish a Funding Opportunity Announcement for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)

NCI Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-CA-20-042)

MTEC Interoperable Medical Automated Systems (iMAS) Technology and Gap Assessment

OSC Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NLM Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)

CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health

Booz Allen Foundation: Innovation Grant

Spencer Foundation

Emergency Response for the  General Public Innovation Challenge

Social Data Research Fellowships

Emergency Response for the Health Care System Challenge (Robert Wood Johnson Foundation partnership with Catalyst @ Health 2.0)

AHRQ Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)

CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health

CDMRP PRMRP Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health

Joint NSF-BSF Programs Dealing with the Coronavirus Disease

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)

Social Science Research Council (SSRC)

Russell Sage Foundation

Cures within Reach: Chicago Area-Focused Repurposing Research

NLM Notice of Special Interest (NOSI): Availability of Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) (NOT-LM-20-010)

AHRQ Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement – Clinical Trial Optional) (PA-20-070)

NIDDK Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK (NOT-DK-20-018)

NIDDK Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK’s Mission (NOT-DK-20-020)

NIDCD Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)

FSM Institute for Global Health Research Catalyzer Fund

PCORI NOTICE OF INTENT: COVID-19 Targeted Funding Announcement

Facebook: Economic Impact of Digital Technologies

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NSF Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) (NSF 20-055)

NHGRI Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-HG-20-030)

AXA Research Fund: Mitigating Risk in the Wake of the COVID-19 Pandemic

Children, Screens and COVID-19

MTEC Wearable Diagnostic for Detection of COVID-19 Infection 

Office of Minority Health (OMH) National Infrastructure for Mitigating the Impact of COVID-19 within Racial and Ethnic Minority Communities (MP-CPI-20-006)

C3.ai DTI COVID-19 Research Award

Humanitarian solutions for COVID-19

MTEC National Emergency Telecritical Care Network (NETCCN) Project

NIGMS Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19 

Biomedical Advanced Research and Development Authority (BARDA) BAA Amendment

NUCATS COVID-19 Rapid Response Grants

CDC COVID-19 Broad Agency Announcement

NIAID/NIGMS Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus 

MTEC Development of Treatments for COVID-19 Technologies

AHA Rapid Response Grant: COVID-19 and its Cardiovascular Impact

LifeArc COVID-19 Fund

Resources

Federal Agency Information and Resources

Northwestern University Information and Resources

Coronavirus/COVID-19 Updates

Feinberg COVID-19 Task Force
The Feinberg School of Medicine Dean Eric G. Neilson, MD, has created a COVID-19 Task Force to provide a coordinating function and to:  1) connect appropriate projects with clinical information and samples; 2) provide recommendations to the Dean; and 3) encourage people with similar ideas to work together.  The task force has identified three current focus areas: 1) interventional studies; 2) data and analytics; and 3) discovery, diagnostics and specimens. The task force will be cataloging all COVID-19-related research being performed by Feinberg faculty and staff. We are already collecting projects submitted to the Institutional Review Board, the Institutional Biosafety Committee and the Office of Sponsored Research. NUCATS is also offering a rapid feasibility and infrastructure alignment review to help investigators efficiently operationalize Feinberg and health system resources for COVID-19 research.  If you are starting or contemplating a project that has not been submitted to one of these units, please send a short one paragraph description to Rex Chisholm (r-chisholm@northwestern.edu) and Abby Cosentino-Boehm, DrPh (a-cosentino-boehm@northwestern.edu).

COVID-19 Resources for Funding, Publications, Data, and Teaming

Core Facilities Status

Feinberg COVID-19 Information Page

Institute for Global Health COVID-19 Resources

Galter Health Science Library & Learning Center COVID-19/Coronavirus Update

NUCATS COVID-19 Resource Page

Office for Research COVID-19 Guidance for Researchers

OSR COVID-19 Information for Sponsored Research Administration

ARCC Resources for Community-Engaged Research Partnerships During COVID-19 Pandemic